Xin Lang Cai Jing·2025-12-15 07:28Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise established in 1998, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization, aiming to provide high-quality and effective medications and services globally [2][3]. Group 1: Company Overview - Haiprui's main business segments include heparin raw materials, downstream low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin raw materials [7]. - As of September 30, 2025, Haiprui reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. - The company has a total market capitalization of 17.123 billion yuan, with a trading volume of 33.7636 million yuan and a turnover rate of 0.23% on December 15 [1]. Group 2: Financial Performance - The overseas revenue contribution for Haiprui is 93.04%, benefiting from the depreciation of the Renminbi [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Group 3: Market Position and Trends - Haiprui operates in the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors including biopharmaceuticals, raw materials, vaccines, and innovative drugs [7]. - The stock has shown a net inflow of 605,300 yuan from major investors, indicating a lack of clear trend in major holdings, with the stock's average trading cost at 11.59 yuan [5][6].